Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Fennec Pharmaceuticals Inc(FENC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FENC
11/09/2026: FENC (1-star) is currently NOT-A-BUY. Pass it for now.
Fennec Pharmaceuticals is a commercial-stage biotechnology company that has successfully launched PEDMARK, a specialized treatment designed to reduce hearing loss in children receiving cisplatin chemotherapy. The company's primary strength lies in its regulatory exclusivity and clear niche within pediatric oncology supportive care. Its main growth story is centered on the ongoing commercial adoption of PEDMARK across U.S. hospital networks. Key risks include the company's reliance on a single product, competition from off-label therapies, and the challenges of execution for a small commercial team. Fennec may suit growth-oriented investors with a high risk tolerance, and shareholders should monitor revenue adoption trends and new market expansion updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential tied to the adoption of a single flagship product in a niche oncology market. |
| Momentum investor | Mixed fit | Momentum is conditional on positive signals regarding product adoption rates and hospital formulary wins. |
| Value investor | Weak fit | The valuation is primarily driven by future growth expectations rather than current earnings multiples. |
| Dividend investor | Weak fit | Fennec is a growth-oriented biotech that does not currently provide dividend income. |
| Low-risk investor | Weak fit | Small-cap biotech stocks carry significant inherent volatility and business-specific risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotechnology stocks often experience sharp price fluctuations based on commercial milestones. |
| Valuation risk | Medium / high | Valuations are highly sensitive to projections of product adoption and revenue growth. |
| Competition risk (oncology therapeutics) | Medium | The company must compete against established standards of care and future generic or pharmaceutical alternatives. |
| Business quality | Medium | The business relies heavily on the commercial success of one primary product. |
| Dividend income | Low / none | The company does not pay dividends and reinvests all capital. |
| Execution risk | Medium / high | Successful market penetration in the pediatric oncology space requires significant sales and marketing execution. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 16.23% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/09/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 344.01M USD | Price to earnings Ratio - | 1Y Target Price 17.2 |
Price to earnings Ratio - | 1Y Target Price 17.2 | ||
Volume (30-day avg) 134.1K shares | Beta 1.21 | 52 Weeks Range 5.65 - 13.25 | Updated Date 11/08/2026 |
52 Weeks Range 5.65 - 13.25 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Therapeutics | Revenue generated from the sale of PEDMARK in the U.S. market. | The company makes money by selling a specialized drug that prevents hearing loss in children undergoing chemotherapy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-12 | When Before Market | Estimate 0.09 | Actual - |
Profitability
Profit Margin -5.49% | Operating Margin (TTM) 9.72% |
Management Effectiveness
Return on Assets (TTM) -1.17% | Return on Equity (TTM) -18.58% |
Valuation
Trailing PE - | Forward PE 11.17 | Enterprise Value 295.91M | Price to Sales(TTM) 5.81 |
Enterprise Value 295.91M | Price to Sales(TTM) 5.81 | ||
Enterprise Value to Revenue 5.01 | Enterprise Value to EBITDA 20.27 | Shares Outstanding 35.07M | Shares Floating 19.84M |
Shares Outstanding 35.07M | Shares Floating 19.84M | ||
Percent Insiders 14.19 | Percent Institutions 56.24 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.